CVE-2010-5097

Description

Cross-site scripting (XSS) vulnerability in the click enlarge functionality in TYPO3 4.3.x before 4.3.9 and 4.4.x before 4.4.5 when the caching framework is enabled, allows remote attackers to inject arbitrary web script or HTML via unspecified vectors.

Category

2.6
CVSS
Severity: Low
CVSS 2.0 •
EPSS 0.65%
Vendor Advisory typo3.org
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
http://typo3.org/teams/security/security-bulletins/typo3-core/typo3-sa-2010-022/ vendor advisory
http://www.securityfocus.com/bid/45470 vdb entry
http://secunia.com/advisories/35770 third party advisory
https://exchange.xforce.ibmcloud.com/vulnerabilities/64178 vdb entry
http://www.openwall.com/lists/oss-security/2012/05/12/5 mailing list
http://www.openwall.com/lists/oss-security/2011/01/13/2 mailing list
http://www.openwall.com/lists/oss-security/2012/05/11/3 mailing list
http://www.osvdb.org/70123 vdb entry
http://www.openwall.com/lists/oss-security/2012/05/10/7 mailing list

Frequently Asked Questions

What is the severity of CVE-2010-5097?
CVE-2010-5097 has been scored as a low severity vulnerability.
How to fix CVE-2010-5097?
To fix CVE-2010-5097, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2010-5097 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2010-5097 is being actively exploited. According to its EPSS score, there is a ~1% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.